drugset
drugset / Trial / NCT03084289

A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration

NCT03084289 ↗

Phase 1 Completed 26 enrolled University of Oxford
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of novel routes of administration of the candidate malaria vaccines ChAd63 encoding ME-TRAP and MVA encoding ME-TRAP. 30-33 Healthy adult volunteers will be recruited in Oxford. All vaccinations will be administered intravenously or subcutaneously. Each volunteer will receive a single vaccination of ChAd63 ME-TRAP or MVA ME-TRAP at different doses depending on the group.

Timeline

Start
2017-03-28
Primary completion
2020-07-06
Completion
2020-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ChAd63 ME-TRAP Vaccine 5e+08 unknown Intravenous
Subject ChAd63 ME-TRAP Vaccine 5e+09 unknown Intravenous
Subject ChAd63 ME-TRAP Vaccine 5e+10 unknown Intravenous
Subject ChAd63 ME-TRAP Vaccine 2e+11 unknown Intravenous
Subject MVA ME-TRAP Vaccine 2e+06 unknown Intravenous
Subject MVA ME-TRAP Vaccine 2e+07 unknown Intravenous
Subject MVA ME-TRAP Vaccine 2e+08 unknown Intravenous

Indications

malaria